“This is the time to stand up together and say “no” to what the [US] Administration is doing,” said a pharmaceutical industry executive during a January 2025 conference call. Since then, President Tru
The Maryland Prescription Drug Affordability Board (PDAB) does not automatically assume an upper payment limit is the go-to solution for drug affordability concerns, Executive Director Andrew York sai
The pharmaceutical industry in Europe has criticized the Council of the EU’s adoption of a package of legislative reforms for medicines, claiming that the continent’s innovation-unfriendly environment
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Will Try Camurus’s FluidCrystal D